RNA-editing Drugs
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
64
NCT06677307
A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110
Phase: Phase 1/2
Role: Lead Sponsor
Start: Jan 13, 2025
Completion: Dec 31, 2026
Loading map...